Skip to content

Human Psychopharmacology: Clinical and Experimental

ISSN 0885-6222, 1099-1077

69 papers in the library · 3,797 citations · publishing 1988-2026

Papers

Sort Most recent Most cited

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives

Human Psychopharmacology: Clinical and Experimental September 1, 2026 José Norberto Vásquez-Bonilla

OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A...

Investigating Hypo‐Egoic Features: Ayahuasca's Psychedelic Path Versus Meditation's Mindful Journey

Human Psychopharmacology: Clinical and Experimental May 1, 2026 María Arqueros, J L Fayos Soler, Ausiàs Cebolla et al.

OBJECTIVE: 'Ego dissolution' refers to a temporary state characterized by diminished self-referential processing, which leads to a breakdown of personal boundaries and an enhanced sense of unity with the environment. Both psychedelics, such as ayahuasca, and contemplative practices, like meditation, have been proposed as mechanisms for modulating the ego. While ayahuasca induces transient...

Pharmacological Management of Anxiety in End‐of‐Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin

Human Psychopharmacology: Clinical and Experimental 2026 Brunno Freitas Da Costa, Paula Hartmann, Daniel Pagnin

ABSTRACT Objective Anxiety is common in patients receiving end‐of‐life care and significantly impacts their quality of life. However, pharmacological management remains challenging due to complex clinical presentations and potential side effects, emphasizing the need for systematically reviewing existing treatments. Here we aim to systematically evaluate the efficacy and safety of...

Effects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination.

Human Psychopharmacology: Clinical and Experimental September 1, 2025 Renée Martin-Willett, Carillon J. Skrzynski, Angela D Bryan et al.

This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research. Participants were either not using cannabis, using cannabis with THC, or...

Efficacy of Intranasal Esketamine in Treatment-Resistant Depression: A Six-Month Real-World Follow-Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk.

Human Psychopharmacology: Clinical and Experimental July 1, 2025 Maurizio Pompili, Maria Anna Trocchia, Ludovica Longhini et al. 3 citations

Treatment-resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real-world outpatient setting. A secondary objective was to explore the potential benefits of intranasal esketamine on hopelessness and suicide risk...

Trajectories of sentiment in 11,816 psychoactive narratives

Human Psychopharmacology: Clinical and Experimental December 20, 2023 Sam Friedman, Galen Ballentine 5 citations

Abstract Objective Can machine learning (ML) enable data‐driven discovery of how changes in sentiment correlate with different psychoactive experiences? We investigate by training models directly on text testimonials from a diverse 52‐drug pharmacopeia. Methods Using large language models (i.e. BERT) and 11,816 publicly‐available testimonials, we predicted 28‐dimensions of sentiment across each...

DOI: 10.1002/hup.2889 (opens in new tab) Narrative Surprise Parallels Cognitive psychology

Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships.

Human Psychopharmacology: Clinical and Experimental May 1, 2022 Jason B. Luoma, Ben Shahar, M Kati Lear et al. 26 citations

Researchers have suggested that psychotherapy may be enhanced by the addition of 3,4-methylenedioxymethamphetamine (MDMA), particularly in the treatment of disorders wherein interpersonal dysfunction is central, such as social anxiety disorder. We review literature pertaining to three potential processes of change that may be instigated during sessions involving MDMA administration in the...

DOI: 10.1002/hup.2824 (opens in new tab) Full text (opens in new tab) MDMA Memory reconsolidation Processes of change Self-transcendence +2

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression

Human Psychopharmacology: Clinical and Experimental February 18, 2022 A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo et al. 39 citations

Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days...

N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine

Human Psychopharmacology: Clinical and Experimental February 17, 2022 Edward James, Joachim Keppler, Ben Sessa et al. 41 citations

Abstract Objective Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post‐traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N‐dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of...

Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof‐of‐concept, randomized, placebo‐controlled trials

Human Psychopharmacology: Clinical and Experimental February 2, 2022 Rafael G. Dos Santos, Juliana Mendes Rocha, Giordano Novak Rossi et al. 20 citations

Abstract Objective To assess endocannabinoid (anandamide, AEA; 2‐arachidonoylglycerol, 2‐AG) plasma levels in healthy volunteers and in volunteers with social anxiety disorder (SAD) after a single oral dose of ayahuasca or placebo. Methods Post hoc analysis of endocannabinoid plasma levels (baseline, 90 and 240 min after drug intake) from two parallel‐group, randomized, placebo‐controlled...

DOI: 10.1002/hup.2834 (opens in new tab) Ayahuasca Anxiety Placebo Endocannabinoid system +4

Serotonin transporter availability, neurocognitive function and their correlation in abstinent 3,4‐methylenedioxymethamphetamine users

Human Psychopharmacology: Clinical and Experimental 2022 Foke L. Van de Blaak, Glenn Dumont

AbstractRationaleMDMA or Ecstasy has made a resurgence in popularity and the majority of users consist of teenagers and adolescents. Therefore, it is important to determine whether MDMA causes long‐term damage and what this damage entails. There is an ongoing debate about possible neurocognitive changes in 3,4‐methylenedioxymethamphetamine (MDMA) users related to MDMA's neurotoxic potential....

The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta‐analysis of randomised controlled trials in healthy volunteers

Human Psychopharmacology: Clinical and Experimental November 5, 2021 Hang Li, Yi Zhong, Siyuan Yang et al. 7 citations

In recent years, interest in using lysergic acid diethylamide (LSD) in psychiatric research and corresponding therapy has increased rapidly. In this meta‐analysis, we explored the effects of LSD on healthy subjects with respect to subjective drug effects, blood pressure, heart rate, body temperature and side effects.

Ayahuasca may help to improve self‐compassion and self‐criticism capacities

Human Psychopharmacology: Clinical and Experimental August 19, 2021 Elisabet Domínguez‐clavé, Joaquim Soler, Matilde Elices et al. 30 citations

Abstract Objective Ayahuasca is a psychedelic brew that originated in the Amazon basin. The psychological effects of this drug are becoming better understood due to the growing research interest in identifying new potential therapeutic agents for the treatment of emotion dysregulation and other disorders. Previous studies suggest that ayahuasca enhances mindfulness‐related capacities...

Psilocybin occasioned mystical‐type experiences

Human Psychopharmacology: Clinical and Experimental June 23, 2020 Edward James, Thomas L Robertshaw, Mathew Hoskins et al. 29 citations

Abstract Objective Research into psychedelic therapy models has shown promise for the treatment of specific psychiatric conditions. Mystical‐type experiences occasioned by psilocybin have been correlated with therapeutic benefits and long‐term improvements in positive mental outlook and attitudes. This article aims to provide an overview of the topic, highlight strengths and weaknesses in...

DOI: 10.1002/hup.2742 (opens in new tab) Psilocybin Mysticism Psychotherapist Psychological intervention +3

How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy.

Human Psychopharmacology: Clinical and Experimental May 1, 2020 Laura Orsolini, Stefania Chiappini, Duccio Papanti et al. 27 citations

Ayahuasca is a hallucinogenic plant preparation, traditionally consumed in sacred ceremonies by indigenous North-Westerner Amazonian countries like Colombia, Peru, Brazil, and Ecuador. It is fundamental to carefully balance benefits/risks related to the ayahuasca intake, both during ceremonies and experimental settings. The aim is at evaluating and comparing the potential therapeutic benefits...

A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines

Human Psychopharmacology: Clinical and Experimental 2020 Patricia Acosta, Joseph J Palamar 44 citations

Abstract Objective The number of novel psychedelic phenethylamines and tryptamines has continued to increase, but little academic research has focused on the effects of these substances. We sought to determine and compare the subjective effects of various substances. Methods We conducted in‐depth interviews with 39 adults (75.4% male and 87.2% White) who reported experience using psychedelic...

Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4‐fluoroamphetamine intoxication

Human Psychopharmacology: Clinical and Experimental October 25, 2018 Patrick C. Dolder, Elizabeth B. de Sousa Fernandes Perna, Natasha L. Mason et al. 6 citations

OBJECTIVES: 4-Fluoroamphetamine (4-FA) is a novel psychoactive substance with a pharmacological profile and reported subjective effects (e.g., empathy) intermediate between 3,4-methylenedioxymethamphetamine (MDMA) and amphetamine. Studies have shown that MDMA and amphetamine increase emotional empathy without affecting cognitive empathy; MDMA simultaneously leads to elevated levels of oxytocin,...

DOI: 10.1002/hup.2680 (opens in new tab) MDMA Empathy Oxytocin Placebo +4

Low serum level of epidermal growth factor in chronic ketamine users.

Human Psychopharmacology: Clinical and Experimental May 2018 Minling Zhang, Hongbo He, Yuping Ning et al.

Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and...

The detection and prevention of unintentional consumption of DOx and 25x‐NBOMe at Portugal's Boom Festival

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Daniel Martins, Monica J Barratt, Cristiana Vale Pires et al. 76 citations

Abstract Objective This paper describes the misrepresentation of LSD at Portugal's Boom Festival 2014 and the prevention of unintentional consumption of DOx and 25x‐NBOMe among LSD consumers attending a drug‐checking service. Methods Two hundred forty‐five drug samples expected to contain LSD were submitted to the drug‐checking service for chemical analysis. One hundred ten post‐test...

DOI: 10.1002/hup.2608 (opens in new tab) Drug Test biology Consumption sociology Boom +4

The effects and toxicity of cathinones from the users' perspectives: A qualitative study.

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Sulaf Assi, Nargilya Gulyamova, Paul Kneller et al. 35 citations

The objective of this study is to explore the users' perspectives regarding the effects and toxicity of cathinones. A systematic search of Internet discussion forums yielded 303 threads relevant to the research objectives. The threads were analysed by conventional content analysis where concepts were developed from codes and themes. The study identified 3 main themes in relation to cathinone...

DOI: 10.1002/hup.2610 (opens in new tab) Full text (opens in new tab) Cathinones Content analysis Effects Novel psychoactive substances +2

Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Sulaf Assi, Nargilya Gulyamova, Kinda Ibrahim et al. 34 citations

OBJECTIVE: To investigate the profile, effects, and toxicity of novel psychoactive substances (NPS). METHODS: A systematic literature review was conducted between May 2015 and February 2016 and included 19 databases. Search terms included "novel psychoactive substance(s)," "effect(s)," and "toxicity" and their synonyms. Studies included were those from any country, in any language, and between...

Genie in a blotter: A comparative study of LSD and LSD analogues' effects and user profile

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Leigh Coney, Larissa J. Maier, Jason Ferris et al. 18 citations

Abstract Objective This study aimed to describe self‐reported patterns of use and effects of lysergic acid diethylamide (LSD) analogues (AL‐LAD, 1P‐LSD, and ETH‐LAD) and the characteristics of those who use them. Methods An anonymous self‐selected online survey of people who use drugs (Global Drug Survey 2016; N = 96,894), which measured perceived drug effects of LSD and its analogues. Results...

4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study

Human Psychopharmacology: Clinical and Experimental May 1, 2017 Barbara Loi, Mire Zloh, Maria Antonietta De Luca et al. 17 citations

BACKGROUND: 4,4'-DMAR (4,4'-dimethylaminorex; "Serotoni") is a potent stimulant drug that has recently been associated with a number of fatalities in Europe. Over the last few years, online communities have emerged as important resources for disseminating levels of technical knowledge on novel psychoactive substances. OBJECTIVE: Analysing the information provided by the fora communities on...

DOI: 10.1002/hup.2575 (opens in new tab) Netnography Harm reduction Stimulant Scientific literature +3